RecruitingPHASE1, PHASE2NCT06343311
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Studying HIV-associated cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Estrella Biopharma, Inc.
- Principal Investigator
- Pei Wang, PhDEureka Therapeutics Inc.
- Intervention
- EB103(biological)
- Enrollment
- 21 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (2)
- University of California, Davis, Sacramento, California, United States
- Baylor Scott & White Research Institute, Texas Oncology, Dallas, Texas, United States
Collaborators
Eureka Therapeutics Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06343311 on ClinicalTrials.govOther trials for HIV-associated cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07308886Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)National Cancer Institute (NCI)
- RECRUITINGNANCT05561595Transdiagnostic Intervention to Reduce Internalized Health-Related StigmaUniversity of Florida
- ACTIVE NOT RECRUITINGNCT06480773Kaposi Sarcoma Chemotherapy and Research (KS-CARE)UNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE1NCT04902443Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT04941274Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaNational Cancer Institute (NCI)